176 related articles for article (PubMed ID: 37037140)
1. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
3. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
[TBL] [Abstract][Full Text] [Related]
4. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
5. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
J Med Chem; 2024 May; ():. PubMed ID: 38809993
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
9. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
10. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
11. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
Xiong S; Song K; Xiang H; Luo G
Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
[TBL] [Abstract][Full Text] [Related]
12. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
13. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
14. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a multi-target compound for estrogen receptor-positive (ER
Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
[TBL] [Abstract][Full Text] [Related]
19. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
[TBL] [Abstract][Full Text] [Related]
20. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]